Product Information
PREMARIN 0.9 MG TABLET is a brand product labeled by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., priced at $6.9313 per EA under NDC 00046110381. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.9 mg/1
NDC
00046110381
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ESTROGENS, CONJUGATEDApproval Type
New Drug (NDA)
FDA Application
NDA004782FDA Approved
Before 1982
TE Code
AB
On Market Since
1/1/2006
Pharmacological Classes
Price Statistics
The NADAC for PREMARIN 0.9 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 148.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.9313 per EA |
|---|---|
| All-time high | $6.9555 (Jun 10, 2026) |
| All-time low | $2.7911 (Nov 28, 2013) |
| 52-week high | $6.9555 |
| 52-week low | $6.7635 |
| Median price | $5.6827 |
| Average price | $5.4257 |
| Largest weekly change | +9.4% (Jun 11, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the estrogens, conjugated market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
estrogens, conjugated market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Estrogen class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PREMARIN 0.9 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PREMARIN 0.9 MG TABLET, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., is $6.9313 per EA (NDC 00046110381), effective Sep 30, 2026.
How has the price of PREMARIN 0.9 MG TABLET changed over time?
Over the history we have for it, the NADAC for PREMARIN 0.9 MG TABLET has risen 148.3%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for PREMARIN 0.9 MG TABLET?
Since Nov 28, 2013, the NADAC for PREMARIN 0.9 MG TABLET has ranged from a low of $2.7911 (Nov 28, 2013) to a high of $6.9555 (Jun 10, 2026), with a median of $5.6827 per EA.
Are there cheaper alternatives to PREMARIN 0.9 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PREMARIN 0.9 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PREMARIN 0.9 MG TABLET?
PREMARIN 0.9 MG TABLET (NDC 00046110381) is labeled by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., and CMS classifies it as a brand product.